Management of Pump Thrombosis in Patients with Left Ventricular Assist Devices

John M. Stulak, Shashank Sharma, Simon Maltais

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The gradual evolution of left ventricular assist device (LVAD) therapy has resulted in a durable option for patients as either a bridge to transplantation (BTT) or a destination therapy (DT). Outcomes with current continuous-flow devices continue to demonstrate significant patient benefit, not only in enhanced survival but also in improved functional capacity and quality of life. While the lessening of adverse events through time has resulted in more widespread adoption of this therapy, there continues to be unintended consequences, including, most notably, infection, bleeding, and thrombosis. Beginning in 2011, centers and collaborative groups began to observe a significant increase in the incidence of pump thrombosis with the HeartMate II LVAD (Thoratec Corp., Pleasanton, CA, USA). However, this clinical scourge is not limited to the HeartMate II, as the HeartWare Ventricular Assist System (HVAD; HeartWare Inc., Framingham, MA, USA) has also had these same issues, which led to pump modifications and the appreciation of more strict control of blood pressure and anticoagulation with this pump design. We review the current status of the field of mechanical circulatory support in its approach to diagnosis, management, and prevention of LVAD pump thrombosis.

Original languageEnglish (US)
Pages (from-to)89-94
Number of pages6
JournalAmerican Journal of Cardiovascular Drugs
Volume15
Issue number2
DOIs
StatePublished - Apr 1 2015
Externally publishedYes

Fingerprint

Heart-Assist Devices
Thrombosis
Therapeutics
Transplantation
Quality of Life
Hemorrhage
Blood Pressure
Equipment and Supplies
Survival
Incidence
Infection

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Management of Pump Thrombosis in Patients with Left Ventricular Assist Devices. / Stulak, John M.; Sharma, Shashank; Maltais, Simon.

In: American Journal of Cardiovascular Drugs, Vol. 15, No. 2, 01.04.2015, p. 89-94.

Research output: Contribution to journalArticle

@article{266979d5e1e3441ea507a93fa81b2dec,
title = "Management of Pump Thrombosis in Patients with Left Ventricular Assist Devices",
abstract = "The gradual evolution of left ventricular assist device (LVAD) therapy has resulted in a durable option for patients as either a bridge to transplantation (BTT) or a destination therapy (DT). Outcomes with current continuous-flow devices continue to demonstrate significant patient benefit, not only in enhanced survival but also in improved functional capacity and quality of life. While the lessening of adverse events through time has resulted in more widespread adoption of this therapy, there continues to be unintended consequences, including, most notably, infection, bleeding, and thrombosis. Beginning in 2011, centers and collaborative groups began to observe a significant increase in the incidence of pump thrombosis with the HeartMate II LVAD (Thoratec Corp., Pleasanton, CA, USA). However, this clinical scourge is not limited to the HeartMate II, as the HeartWare Ventricular Assist System (HVAD; HeartWare Inc., Framingham, MA, USA) has also had these same issues, which led to pump modifications and the appreciation of more strict control of blood pressure and anticoagulation with this pump design. We review the current status of the field of mechanical circulatory support in its approach to diagnosis, management, and prevention of LVAD pump thrombosis.",
author = "Stulak, {John M.} and Shashank Sharma and Simon Maltais",
year = "2015",
month = "4",
day = "1",
doi = "10.1007/s40256-014-0102-3",
language = "English (US)",
volume = "15",
pages = "89--94",
journal = "American Journal of Cardiovascular Drugs",
issn = "1175-3277",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Management of Pump Thrombosis in Patients with Left Ventricular Assist Devices

AU - Stulak, John M.

AU - Sharma, Shashank

AU - Maltais, Simon

PY - 2015/4/1

Y1 - 2015/4/1

N2 - The gradual evolution of left ventricular assist device (LVAD) therapy has resulted in a durable option for patients as either a bridge to transplantation (BTT) or a destination therapy (DT). Outcomes with current continuous-flow devices continue to demonstrate significant patient benefit, not only in enhanced survival but also in improved functional capacity and quality of life. While the lessening of adverse events through time has resulted in more widespread adoption of this therapy, there continues to be unintended consequences, including, most notably, infection, bleeding, and thrombosis. Beginning in 2011, centers and collaborative groups began to observe a significant increase in the incidence of pump thrombosis with the HeartMate II LVAD (Thoratec Corp., Pleasanton, CA, USA). However, this clinical scourge is not limited to the HeartMate II, as the HeartWare Ventricular Assist System (HVAD; HeartWare Inc., Framingham, MA, USA) has also had these same issues, which led to pump modifications and the appreciation of more strict control of blood pressure and anticoagulation with this pump design. We review the current status of the field of mechanical circulatory support in its approach to diagnosis, management, and prevention of LVAD pump thrombosis.

AB - The gradual evolution of left ventricular assist device (LVAD) therapy has resulted in a durable option for patients as either a bridge to transplantation (BTT) or a destination therapy (DT). Outcomes with current continuous-flow devices continue to demonstrate significant patient benefit, not only in enhanced survival but also in improved functional capacity and quality of life. While the lessening of adverse events through time has resulted in more widespread adoption of this therapy, there continues to be unintended consequences, including, most notably, infection, bleeding, and thrombosis. Beginning in 2011, centers and collaborative groups began to observe a significant increase in the incidence of pump thrombosis with the HeartMate II LVAD (Thoratec Corp., Pleasanton, CA, USA). However, this clinical scourge is not limited to the HeartMate II, as the HeartWare Ventricular Assist System (HVAD; HeartWare Inc., Framingham, MA, USA) has also had these same issues, which led to pump modifications and the appreciation of more strict control of blood pressure and anticoagulation with this pump design. We review the current status of the field of mechanical circulatory support in its approach to diagnosis, management, and prevention of LVAD pump thrombosis.

UR - http://www.scopus.com/inward/record.url?scp=84939969295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939969295&partnerID=8YFLogxK

U2 - 10.1007/s40256-014-0102-3

DO - 10.1007/s40256-014-0102-3

M3 - Article

C2 - 25567787

AN - SCOPUS:84939969295

VL - 15

SP - 89

EP - 94

JO - American Journal of Cardiovascular Drugs

JF - American Journal of Cardiovascular Drugs

SN - 1175-3277

IS - 2

ER -